MYC and ovarian cancer: CIP2A depletion in ovarian cancer cell lines inhibited proliferation, blocked cell cycle progression, increased paclitaxel-induced apoptosis, downregulated cyclin D1, c-MYC, p-RB, BCL2 and pAKT expression validating the role of CIP2A as a clinically relevant oncoprotein as well as establishing CIP2A as a promising therapeutic target of ovarian cancer [62].